Genes and Development Attend a BioResearch Product Faire

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Erratum (v13,p1050)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Winston, J. T.
Right arrow Articles by Harper, J. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Winston, J. T.
Right arrow Articles by Harper, J. W.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Vol. 13, No. 3, pp. 270-283, February 1, 1999

RESEARCH PAPER
The SCFbeta -TRCP-ubiquitin ligase complex associates specifically with phosphorylated destruction motifs in Ikappa Balpha and beta -catenin and stimulates Ikappa Balpha ubiquitination in vitro

Jeffrey T. Winston,1,5 Peter Strack,4,5 Peggy Beer-Romero,4 Claire Y. Chu,1 Stephen J. Elledge,1,2,3 and J. Wade Harper1,6

1 Verna & Marrs McLean Department of Biochemistry, 2 Department of Molecular and Human Genetics, 3 Howard Hughes Medical Institute, Baylor College of Medicine, Houston, Texas 77030 USA; 4 Mitotix, Inc., Cambridge, Massachusetts 02139 USA

    Abstract
Top
Abstract
Introduction
Results
Discussion
Materials and methods
References

Ubiquitin-mediated proteolysis has a central role in controlling the intracellular levels of several important regulatory molecules such as cyclins, CKIs, p53, and Ikappa Balpha . Many diverse proinflammatory signals lead to the specific phosphorylation and subsequent ubiquitin-mediated destruction of the NF-kappa B inhibitor protein Ikappa Balpha . Substrate specificity in ubiquitination reactions is, in large part, mediated by the specific association of the E3-ubiquitin ligases with their substrates. One class of E3 ligases is defined by the recently described SCF complexes, the archetype of which was first described in budding yeast and contains Skp1, Cdc53, and the F-box protein Cdc4. These complexes recognize their substrates through modular F-box proteins in a phosphorylation-dependent manner. Here we describe a biochemical dissection of a novel mammalian SCF complex, SCFbeta -TRCP, that specifically recognizes a 19-amino-acid destruction motif in Ikappa Balpha (residues 21-41) in a phosphorylation-dependent manner. This SCF complex also recognizes a conserved destruction motif in beta -catenin, a protein with levels also regulated by phosphorylation-dependent ubiquitination. Endogenous Ikappa Balpha -ubiquitin ligase activity cofractionates with SCFbeta -TRCP. Furthermore, recombinant SCFbeta -TRCP assembled in mammalian cells contains phospho-Ikappa Balpha -specific ubiquitin ligase activity. Our results suggest that an SCFbeta -TRCP complex functions in multiple transcriptional programs by activating the NF-kappa B pathway and inhibiting the beta -catenin pathway.

[Key Words: Ubiquitin ligase; SCF complex; proteolysis; destruction motifs; NF-kappa B; beta -catenin]

    Introduction
Top
Abstract
Introduction
Results
Discussion
Materials and methods
References

The transcription factor NF-kappa B has a central role in cellular stress and inflammatory responses by controlling cytokine-inducible gene expression and lymphocyte stimulation by antigens (Baeuerle and Baltimore 1996; Gilmore et al. 1996). In addition, NF-kappa B is required to block cell death in response to tumor necrosis factor alpha  (TNFalpha ) and ionizing radiation, suggesting that it acts to regulate the transcription of survival genes (Beg and Baltimore 1996; Liu et al. 1996; Van Antwerp et al. 1996; Wang et al. 1996). NF-kappa B is a ubiquitous heterodimeric complex composed of a p65/RelA subunit and a p50 subunit. This complex is normally sequestered in an inactive form in the cytoplasm through interaction with members of a family of inhibitory proteins, the Ikappa Bs (Beg et al. 1992; for review, see Baeuerle and Baltimore 1996). These proteins, when associated with NF-kappa B, obscure the nuclear localization signal in NF-kappa B and also block the ability of NF-kappa B to bind DNA. In response to TNFalpha and other signals, Ikappa Balpha is rapidly phosphorylated on two serine residues near the amino terminus (Ser-32 and Ser-36 in Ikappa Balpha ) (Beg et al. 1993; Finco et al. 1994; Alkalay et al. 1995; Brown et al. 1995; Chen et al. 1995, 1996; DiDonato et al. 1995; Lin et al. 1995). This modification triggers the rapid destruction of Ikappa Balpha by ubiquitin-mediated proteolysis, thereby allowing NF-kappa B nuclear translocation and target gene expression (Chen et al. 1995; Scherer et al. 1995; for review, see Hochstrasser 1996). Recent work has uncovered two Ikappa Balpha kinases, Ikappa Kalpha and Ikappa Kbeta , that are responsible for signal-dependent phosphorylation of Ikappa Balpha (DiDonato et al. 1997; Mercurio et al. 1997; Regnier et al. 1997; Woronicz et al. 1997; Zandi et al. 1997, 1998). These proteins are part of a 700-kD protein complex that is assembled through two structural components Ikappa Kgamma /NEMO and IKAP (Cohen et al. 1998; Rothwarf et al. 1998; Yamaoka et al. 1998) and are activated by cytokines. In vitro, both Ikappa Kalpha and Ikappa Kbeta can phosphorylate Ikappa Balpha specifically on serines 32 and 36, but both kinases are required for efficient Ikappa Balpha phosphorylation in vivo (Zandi et al. 1997).

Although the pathways leading to Ikappa Balpha phosphorylation have been described in detail, little is known about the molecules responsible for ubiquitination. Ubiquitin-mediated proteolysis involves a cascade of ubiquitin transfer reactions in which the ubiquitin-activating enzyme E1 uses ATP to form a high-energy thiolester bond with ubiquitin, which is then transferred to members of the E2 ubiquitin-conjugating enzyme family (Hershko et al. 1983; Hochstrasser 1995). Ubiquitin is then transferred from the E2 to lysine residues in the target through an E3-ubiquitin ligase. E3s serve as adaptors that interact with both the target protein and the appropriate E2, thereby providing specificity to the ubiquitin transfer reaction. In some cases, the E3 is also involved in ubiquitin transfer (Scheffner et al. 1995; Rolfe et al. 1995). Multiple rounds of ubiquitination of the initial conjugates lead to polyubiquitination, which targets the protein for proteolysis by the 26S proteasome. Recent studies have elaborated a modular ubiquitin ligase complex, the SCF-ubiquitin ligase, which mediates phosphorylation-dependent ubiquitination of a large number of proteins (for review, see Elledge and Harper 1998; Patton et al. 1998b). The SCF is composed of Skp1, Cdc53/Cul1, and a specificity-conferring F-box protein (Bai et al. 1996; Feldman et al. 1997; Skowyra et al. 1997; Patton et al. 1998a). F-box proteins contain two domains, an F-box motif that binds Skp1 and allows assembly into Skp1/Cdc53 complexes, and a second protein-protein interaction domain that interacts specifically with one or more target proteins (Bai et al. 1996). Cdc53/Cul1, in turn, interacts with both the E2 and the Skp1/F-box protein complex (Skowyra et al. 1997; Patton et al. 1998a). SCF complexes mediate phosphorylation-dependent destruction of a wide array of regulatory proteins in yeast, including the Cdk inhibitors Sic1, Far1, and Rum1, G1 cyclins, the transcription factor Gcn4, and the DNA replication initiator proteins Cdc6 and Cdc18 (for review, see Elledge and Harper 1998; Patton et al. 1998b). In contrast with yeast, targets of vertebrate SCF complexes remain largely unknown. Previously, we identified four vertebrate proteins that contain the F-box motif, linking them to the ubiquitin pathway: mammalian cyclin F, Skp2, MD6, and Xenopus beta -TRCP (beta -transducin repeat-containing protein; Bai et al. 1996). beta -TRCP was originally identified as a suppressor of a temperature-sensitive mutation in the budding yeast CDC15 gene (Spevak et al. 1993), but its mechanism of suppression has not been determined. Recent genetic evidence has implicated Xenopus beta -TRCP and its Drosphila homolog, slimb, in control of proteolysis in the Hedgehog and Wingless/Wnt signaling pathways (Jiang and Struhl 1998; Marikawa and Elinson 1998).

We have used biochemical approaches to examine whether Ikappa Balpha ubiquitination might involve an SCF-ubiquitin ligase. Here we report that mammalian beta -TRCP binds to the Ikappa Balpha destruction motif in a phosphorylation-dependent manner, thereby recruiting Ikappa Balpha into an SCF-ubiquitin ligase complex. Moreover, SCFbeta -TRCP components cofractionate with Ikappa Balpha -ubiquitin ligase activity from tissue culture cells and SCFbeta -TRCP can stimulate ubiquitination of phosphorylated but not unphosphorylated Ikappa Balpha in an in vitro reconstitution assay. We also demonstrate that the same SCFbeta -TRCP complex recognizes a similar destruction motif in beta -catenin, a component of the TCF/Lef transcription factor complex that functions downstream of Wingless/Wnt (for review, see Peifer 1997) and whose levels are also controlled by phosphorylation-dependent ubiquitin-mediated proteolysis (Aberle et al. 1997). Our results, together with the effects of loss-of-function mutations in the Drosophila beta -TRCP homolog slimb (Jiang and Struhl 1998), suggest that a single SCFbeta -TRCP complex functions in diverse signaling pathways that impinge on transcription control mediated by cytokines (NF-kappa B), Wnt/Wingless (beta -catenin), and Hedgehog [Cubitus interruptus (Ci)].

    Results
Top
Abstract
Introduction
Results
Discussion
Materials and methods
References

Phosphorylation-dependent association of the Ikappa Balpha destruction motif with Skp1

Ikappa Balpha contains two serine residues at positions 32 and 36 that are specifically phosphorylated by the Ikappa K complex in response to TNFalpha stimulation. Phosphorylation of both of these residues is required for Ikappa Balpha ubiquitination in vivo. Previous studies have shown that a 21-amino-acid phosphopeptide containing this destruction motif can block Ikappa Balpha -ubiquitin ligase activity in crude cell extracts and can block NF-kappa B activation in tissue culture cells (Yaron et al. 1997). In addition, this destruction motif can confer signal-dependent destruction when fused to heterologous proteins (Wulczyn et al. 1998). Given the role for SCF complexes in phosphorylation-dependent ubiquitination of various regulatory proteins, we sought to determine whether SCF complexes might be involved in Ikappa Balpha ubiquitination. Synthetic 21-residue peptides encompassing the Ikappa Balpha destruction motif in either the doubly phosphorylated or unphosphorylated forms (Fig. 1a) were immobilized on agarose beads and incubated with HeLa cell lysates. Proteins stably associated with these beads were then examined for the presence of Skp1 by immunoblotting (Fig. 1b). Skp1 was readily detected in proteins bound to the phospho-Ikappa Balpha peptide but not the unphosphorylated peptide. We estimate that ~1% of the total Skp1 in these lysates stably associated with the phospho-Ikappa Balpha peptide under these conditions.


View larger version (38K):
[in this window]
[in a new window]
 
Figure 1.   The F-box protein beta -TRCP associates with phosphorylated destruction motifs in Ikappa Balpha and beta -catenin. (a) Sequences of the Ikappa Balpha (p21) and beta -catenin peptides used in this study. The positions of phosphorylation in the peptides are shown as is the consensus sequence for the destruction motif. (phi ) Hydrophobic amino acid. (b) Phosphorylation-specific association of the Ikappa Balpha destruction motif with Skp1 in vitro. HeLa cell proteins (600 µg) were incubated with phosphorylated or unphosphorylated Ikappa Balpha peptides (p21) immobilized on beads. Bound proteins were immunoblotted with anti-Skp1 antibodies. Approximately 1% of the Skp1 contained in these lysates remained bound to the phosphorylated Ikappa Balpha beads. (c) beta -TRCP specifically associated with phosphorylated Ikappa Balpha and beta -catenin destruction motifs. A panel of [35S]methionine-labeled in vitro-translated F-box proteins was used in binding reactions with Ikappa Balpha (lanes 1-3) or beta -catenin (lanes 4-6) peptide beads. Bound proteins were analyzed by SDS-PAGE and autoradiography. (Right) The domain structures of each F-box protein. (d) The pattern of expression of beta -TRCP at day 11.5 during mouse development was determined by in situ hybridization. The dark-field signal from the beta -TRCP riboprobe is shown in red. (hb) Hindbrain; (fb) forebrain; (h) heart; (l) lung; (li) liver. (e) Chromosomal localization of beta -TRCP. A bacmid containing human beta -TRCP DNA was hybridized to metaphase chromosomes (blue) and detected using fluorescein. The position of hybridization (yellow) is 10q24 (indicated by arrows). (f) beta -TRCP is localized in the cytoplasm. HeLa cells were transiently transfected with pCMV-HA-beta -TRCP and subcellular localization determined after 48 hr by indirect immunofluorescence. Anti-HA localization, red; nuclei stained with DAPI, blue.

Recognition of phosphorylated destruction motifs in Ikappa Balpha and beta -catenin by the WD-40 repeat-containing F-box protein beta -TRCP

The ability of a phospho-Ikappa Balpha peptide to associate with Skp1 suggested the existence of an F-box protein capable of recognizing the Ikappa Balpha destruction motif. Our previous studies identified three vertebrate F-box proteins (Skp2, MD6, and Xenopus beta -TCRP) based on homology to the F-box sequence in human cyclin F and the budding yeast protein Cdc4 (Bai et al. 1996). Recently, we have identified cDNAs encoding 20 distinct mouse and/or human F-box proteins, including the WD-40 repeat-containing protein beta -TRCP, a leucine-rich repeat containing F-box protein F1, and a number of F-box proteins lacking known protein-protein interaction motifs outside the F-box (Fig. 1c; J. Winston, S.J. Elledge, and J.W. Harper, in prep.). Using in vitro translation products, we asked whether members of a collection of these F-box proteins could associate with Ikappa Balpha peptides. Only one, beta -TRCP, was found to associate with the phospho-Ikappa Balpha destruction motif, and this interaction was dependent on phosphorylation (Fig. 1c). Mouse and human beta -TRCP are 95% identical and both interact equally well with Ikappa Balpha in this assay (data not shown for human beta -TRCP). Our analysis included two other WD-40-containing F-box proteins, human MD6 and Met30, the closest homolog of beta -TRCP in budding yeast (31% identity). Importantly, neither of these proteins associated with phospho-Ikappa Balpha (Fig. 1c), suggesting that the interaction of beta -TRCP with phospho-Ikappa Balpha is highly specific.

Previous studies in Drosophila have demonstrated that mutations in the beta -TRCP homolog slimb led to accumulation of Armadillo, the Drosophila homolog of beta -catenin (Jiang and Struhl 1998). beta -Catenin is known to be ubiquitinated in a glycogen synthase kinase 3beta (GSK3beta )-dependent manner and contains a motif within a cluster of candidate GSK3beta phosphorylation sites that is closely related to the Ikappa Balpha destruction motif (Fig. 1a; Ikeda et al. 1998). Although the GSK3beta phosphorylation sites in beta -catenin are not known, we hypothesized based on the sequence similarity between Ikappa Balpha and beta -catenin that Ser-33 and Ser-37 might represent relevant phosphorylation sites. A beta -catenin-derived peptide containing phosphoserine residues at these two positions associated with beta -TRCP but not other F-box proteins tested, whereas the unphosphorylated peptide failed to associate with beta -TRCP (Fig. 1c).

NF-kappa B is a ubiquitous transcription factor. As assessed by in situ hybridization, beta -TRCP is also expressed throughout the developing mouse embryo (day 11.5 postcoitum), with the highest levels in the brain, lung, and liver (Fig. 1d). beta -TRCP is largely, if not exclusively, cytoplasmic, as assessed in HeLa cells transiently expressing an HA-tagged beta -TRCP protein (Fig. 1f). The gene for human beta -TRCP lies on chromosome 10q24, as determined by in situ hybridization of metaphase chromosomes with beta -TRCP genomic DNA (Fig. 1e). Cytogenetic data indicate that this region of the genome is altered in a limited number of cancer types (see Discussion).

Association of SCFbeta -TRCP with Ikappa Balpha and beta -catenin destruction motifs

Having identified beta -TRCP as a candidate F-box protein for Ikappa Balpha and beta -catenin, we next sought to demonstrate that beta -TRCP forms an SCF complex in mammalian cells and that this complex recognizes Ikappa Balpha and beta -catenin destruction motifs. Although there are six mammalian Cullin homologs, the interaction of Skp1 with this family appears to be restricted to Cul1 (Michel and Xiong 1998). 293T cells were transfected with various combinations of plasmids expressing epitope-tagged beta -TRCP, Cul1, or Skp1 and anti-Myc immune complexes from cell lysates analyzed by immunoblotting. beta -TRCPMyc associated with both transfection-derived Skp1HA (Fig. 2a, lanes 4,5) and Cul1HA (lane 5). In contrast, Cul1HA and Skp1HA were not precipitated from control lysates lacking beta -TRCPMyc (lane 6). In the absence of transfection of Skp1 and Cul1, beta -TRCPMyc associated with endogenous Skp1 (lane 3) and Cul1 (data not shown). Analogous results were obtained when Cul1HA was immunoprecipitated with anti-HA antibodies from cells expressing Cul1HA, beta -TRCPMyc, and Skp1Myc (Fig. 2c). Thus, beta -TRCP can form an SCF complex in vivo analogous to that found previously for other F-box proteins (Skowyra et al. 1997; Lisztwan et al. 1998; Lyapina et al. 1998; Michel and Xiong 1998).


View larger version (44K):
[in this window]
[in a new window]
 
Figure 2.   beta -TRCP associates with Skp1 and Cul1 in tissue culture cells. 293T cells were transfected with the indicated plasmids and lysates (0.5 µg of protein/250 µl) used for immunoprecipitation as described in Materials and Methods. Immune complexes or crude lysates from each transfection were analyzed for the presence of Skp1, Cul1, and beta -TRCP by immunoblotting. (a) Anti-beta -TRCPMyc immune complexes. Blots were probed first for beta -TRCP, stripped, and probed for Skp1 and Cul1. The bands indicated by the asterisk indicate the position of beta -TRCP whose antibody was not efficiently stripped from the blot. (b) Crude cell lysates (50 µg) corresponding to extracts used in a. (c) Anti-Cul1HA immune complexes (lanes 1-6) and corresponding cell lysates (50 µg) (lanes 7-13). The positions of both epitope-tagged and endogenous Skp1 are shown.

Next, we asked whether the SCFbeta -TRCP complex could associate with the Ikappa Balpha destruction motif peptide. As shown in Figure 3a, the SCFbeta -TRCP complex readily associated with phosphorylated Ikappa Balpha peptide beads (lanes 6,8,10) but was not retained on unphosphorylated Ikappa Balpha beads (lanes 5,7,9). Although Cul1 associates at low levels with agarose beads containing Ikappa Balpha peptides in the absence of beta -TRCPMyc expression (lanes 11,12) and with agarose beads alone (data not shown), the association with the phospho-Ikappa Balpha peptide was greatly enhanced by expression of beta -TRCPMyc (lane 10). Consistent with the results in Figure 1b, endogenous Skp1 was observed in association with phospho-Ikappa Balpha peptide beads in a phosphorylation-dependent manner in the absence of transfection of beta -TRCP (lanes 1-4), but when the levels of beta -TRCP were increased by transfection, the quantity of endogenous Skp1 associated with beta -TRCP increased substantially (Fig. 3a, lanes 4,6). Analogous results were obtained in a more limited series of binding reactions employing beta -catenin-derived peptides (Fig. 3b).




View larger version (78K):
[in this window]
[in a new window]
 
Figure 3.   Association of SCFbeta -TRCP with Ikappa Balpha and beta -catenin destruction motifs and with the Ikappa Balpha /NF-kappa B complex. (a,b) Cell lysates (0.3 µg of protein/150 µl) from Fig. 2 were used in Ikappa Balpha (a) and beta -catenin (b) peptide bead binding reactions as described in Materials and Methods. Bound proteins were analyzed by immunoblotting with the indicated antibodies. (c) Phosphorylation-dependent association of beta -TRCPMyc with the Ikappa Balpha /p50/p65 complex in vitro. beta -TRCPMyc immune complexes (lanes 2,5) corresponding to those in Fig. 2a (lane 3) or control complexes (lanes 3,6) corresponding to those in Fig. 2a (lane 1) were used in binding reactions with either Ikappa Balpha /p50/p65 or Ikappa K-beta phosphorylated Ikappa Balpha /p50/p65 complexes (see Materials and Methods). Bound proteins were separated by SDS-PAGE and immunoblotted using anti-p50 or anti-Ikappa Balpha antibodies. The asterisk (lanes 1,4) indicates the positions of 15% of the input Ikappa Balpha complexes used in the binding reaction.

Although it was clear that destruction motif peptides can bind the SCFbeta -TRCP complex, it was necessary to demonstrate that this complex also recognized the endogenous ubiquitination substrate, the Ikappa K-phosphorylated Ikappa Balpha /NF-kappa B complex. To generate this substrate, Ikappa Balpha /p50/p65 complexes were produced in insect cells and purified to near homogeneity (Fig. 4a). When incubated with ATP and purified Ikappa K-beta , the Ikappa Balpha protein underwent a mobility shift reminiscent of that observed upon phosphorylation in vivo, and this phosphorylated Ikappa Balpha protein was recognized by phosphospecific antibodies directed at Ser-32 of Ikappa Balpha (Fig. 4b, lane 2). In addition, microsequencing of Ikappa K-treated Ikappa Balpha confirmed that both Ser-32 and Ser-36 were phosphorylated (data not shown). To examine whether SCFbeta -TRCP could recognize this complex, binding reactions were performed using immobilized SCFbeta -TRCP complexes isolated from 293T cells transiently expressing Myc-tagged beta -TRCP or mock transfected cells as a control and either phosphorylated or unphosphorylated Ikappa Balpha /NF-kappa B complexes. The beta -TRCPMyc immune complexes contain endogenous Skp1 (Fig. 2, lane 3) and Cul1 (data not shown) as determined by immunoblotting. Both Ikappa Balpha and p50 were found to associate with the SCFbeta -TRCP complex but not control immune complex in a phosphorylation-dependent manner (Fig. 3c). Similar results were obtained with GST-beta -TRCP complexes purified from insect cells (data not shown).






View larger version (234K):
[in this window]
[in a new window]
 
Figure 4.   Ikappa Balpha -ubiquitin ligase activity from human cells cofractionates with beta -TRCP. (a) Ikappa Balpha /p50/p65 complexes were purified to near homogeneity from insect cells as described in Materials and Methods. Proteins were separated by SDS-PAGE and stained with Coomassie blue. (b) Phosphorylation of the Ikappa Balpha /p50/p65 complex by Ikappa K-beta . The Ikappa Balpha complex (lanes 1,2) or a nonphosphorylatable Ikappa Balpha mutant (S32/36A) complex (lane 3) was incubated in the presence of ATP and Ikappa K-beta as indicated in Materials and Methods. Products were analyzed by immunoblotting with anti-Ikappa Balpha antibodies to detect a mobility shift accompanying phosphorylation that is absent in the nonphosphorylatable mutant (top) or with antibodies that specifically detect the Ser-32-phosphorylated form of Ikappa Balpha (bottom). (c) Ubiquitination of Ikappa Balpha complexes by crude cell lysates was performed as described in Materials and Methods. Phosphorylation leads to a ~10- to 20-fold increase in ubiquitin conjugates relative to the unphosphorylated complex, whereas no activity is observed with the nonphosphorylatable Ikappa Balpha complexes. (d) Inhibition of Ikappa Balpha ubiquitination by phosphorylated Ikappa Balpha destruction motif peptides but not by nonphosphorylatable destruction motif peptides (p19). Ubiquitination reactions were performed with crude cell extracts and Ikappa K-beta phosphorylated Ikappa Balpha complexes in the presence or absence of phosphorylated or nonphosphorylatable destruction motif peptides. Specific inhibition of ubiquitination was observed with the phosphorylated peptide. (e) Cofractionation of beta -TRCP with endogenous Ikappa Balpha -ubiquitin ligase activity. Crude extracts from THP.1 cells were precipitated with ammonium sulfate. Solubilized proteins containing ubiquitin ligase activity were fractionated using a phenyl-Sepharose column and activity in each fraction determined as described in Materials and Methods. Aliquots of column fractions were assayed for beta -TRCP, Cul1, and Skp1 by immunoblotting. Fractions containing beta -TRCP, Cul1, and Skp1 (fractions 7,8) contain Ikappa Balpha -ubiquitin ligase activity.

Biochemical association of endogenous Ikappa Balpha -ubiquitin ligase activity with beta -TRCP

Crude cell lysates from the human monocyte cell line THP.1 contain potent Ikappa Balpha -ubiquitin ligase activity (Fig. 4c). In the context of an Ikappa Balpha /NF-kappa B complex, efficient Ikappa Balpha ubiquitination by these lysates is dependent on phosphorylation by Ikappa K (Fig. 4c). As reported earlier (Yaron et al. 1997), this Ikappa Balpha -ubiquitin ligase activity is strongly inhibited by phosphorylated Ikappa Balpha destruction motif peptides (Fig. 4d, lanes 4,5) but not by nonphosphorylatable destruction box peptides (lanes 2,3). Thus, this assay reiterates the requirements for Ikappa Balpha ubiquitination observed in vivo. Greater than 95% of the Ikappa Balpha -ubiquitin ligase activity in these extracts can be precipitated with 30%-50% ammonium sulfate (Fig. 4e, lane 1) and can be further purified by chromatography on a phenyl-Sepharose column (Fig. 4e; see Materials and Methods). Peak fractions of Ikappa Balpha -ubiquitin ligase activity (Fig. 4e, lanes 8,9) elute at 0.5 M ammonium sulfate.

Having partially purified components of the Ikappa Balpha -ubiquitin ligase, we examined whether beta -TRCP and other SCF components were contained in active fractions from the phenyl-Sepharose column. Skp1 has an extended elution profile, but both Skp1 and Cul1 are contained in the active fractions 7 and 8 (Fig. 4e). Skp1 and Cul1 can interact with multiple F-box proteins, and the identity of the F-box protein in complexes with Cul1 and Skp1 is likely to affect elution properties on phenyl-Sepharose. In contrast with Skp1, beta -TRCP levels peak in fraction 7, as determined using affinity-purified carboxy-terminal antibodies, coincident with maximal activity (Fig. 4e, lane 8). beta -TRCP was also detected in active fraction 8 (Fig. 4e, lane 9). This fraction contained lower levels of Ikappa Balpha -ubiquitin ligase activity, as assessed by the extent of conjugation, consistent with the lower levels of beta -TRCP. As shown below, under some gel conditions the beta -TRCP protein is resolved into a closely spaced doublet of proteins at 58-60 kD. Interestingly, although fraction 6 contains detectable levels of Skp1 and beta -TRCP, it lacks detectable Cul1 and Ikappa Balpha -ubiquitin ligase activity (Fig. 4e, lane 7). Likewise, fraction 9 containing Skp1 and Cul1 but no beta -TRCP is also inactive (Fig. 4e, lane 10).

Consistent with a role for Skp1 in the Ikappa Balpha -ubiquitin ligase, antibodies against Skp1, but not control GST antibodies, deplete Ikappa Balpha -ubiquitin ligase activity from the active phenyl-Sepharose fractions (Fig. 5a). As expected, Skp1 and Cul1 are largely depleted from these active extracts (lane 2). Importantly, the majority of beta -TRCP is also removed by Skp1 antibodies (Fig. 5a, lane 2). beta -TRCP migrated as a closely spaced doublet at 58 and 60 kD. The faster migrating form, corresponding to ~80% of the total, was essentially depleted by anti-Skp1 antibodies (lane 2), when compared with control GST-depleted extracts. The source of the heterogeneity in beta -TRCP is not known at present, but it is possible that the more slowly migrating form is not associated with Skp1 or is dislodged from Skp1 by the anti-Skp1 antibodies. We also note that Cul1 migrated as a doublet (Fig. 5a). The slower migrating form is likely to correspond to a form of the protein conjugated to NEDD8, a homolog of Rub1 that is known to be covalently linked to Cdc53 in budding yeast (for review, see Hochstrasser 1998).


View larger version (31K):
[in this window]
[in a new window]
 
Figure 5.   Depletion of Ikappa Balpha -ubiquitin ligase activity by anti-Skp1 antibodies and destruction motif peptides correlates with removal of beta -TRCP. (a) Ubiquitin ligase activity from phenyl-Sepharose fractions 7 and 8 was depleted with antibodies against Skp1 or GST and the supernatant assayed for ubiquitination activity toward phosphorylated Ikappa Balpha (bottom). The levels of Skp1, Cul1, and beta -TRCP in the supernatants from the depleted fractions were determined by immunoblotting (top). (b,c) Endogenous beta -TRCP associates with phosphorylated Ikappa Balpha destruction motif peptides during depletion of Ikappa Balpha -ubiquitin ligase activity. Crude cell extracts (b) or active fractions from a phenyl-Sepharose column (c) were incubated with beads containing either phosphorylated or nonphosphorylatable Ikappa Balpha peptides and the supernatants assayed for ubiquitin ligase activity (bottom panels). The levels of Skp1, Cul1, and beta -TRCP in the supernatant and associated with destruction motif peptides were determined by immunoblotting (top). beta -TRCP is associated with the phosphorylated destruction motif peptides and is substantially depleted from active ubiquitin ligase fractions.

We also found that phospho-Ikappa Balpha destruction motif peptides (but not the nonphosphorylatable counterparts) were able to deplete ubiquitin ligase activity from both active fractions from the phenyl-Sepharose column (Fig. 5b) and crude cell extracts (Fig. 5c). Skp1, Cul1, and beta -TRCP were all associated with the phosphorylated destruction motif beads but not with the nonphosphorylatable destruction motif (Fig. 5, b, lanes 4 and 5, and c, lanes 3 and 4). Although the levels of Skp1 and Cul1 in supernatants were essentially unaffected (Fig. 5, b, lanes 1-3, and c, lanes 1 and 2), the level of beta -TRCP in the supernatant from both crude and purified fractions was substantially reduced (~80% for the crude lysate and >90% for the phenyl-Sepharose fraction) (Fig. 5b,c, lanes 1,2). These data are consistent with beta -TRCP-associated Skp1 being a small fraction of the total Skp1/Cul1 complexes present in the cell (see Fig. 1b). Currently available antibodies against beta -TRCP were unable to immunodeplete beta -TRCP from crude lysates or purified fractions, prohibiting a direct analysis of the effects of removal of beta -TRCP on Ikappa Balpha -ubiquitin ligase activity. Nevertheless, the finding that depletion of SCFbeta -TRCP from either crude lysates or purified fraction correlates with loss of ubiquitin ligase activity strongly implicates this SCF complex as being involved in Ikappa Balpha ubiquitination.

Stimulation of Ikappa Balpha ubiquitination by an SCFbeta -TRCP complex in vitro

The results described thus far are consistent with a role for SCFbeta -TRCP in Ikappa Balpha ubiquitination. If beta -TRCP functions as a specificity factor for ubiquitination of Ikappa Balpha through an SCF-dependent pathway, it should be possible to confer Ikappa Balpha ubiquitination activity by introducing beta -TRCP into a system that lacks such an activity. Although budding yeast contains a number of E2 enzymes that could potentially support Ikappa Balpha ubiquitination, its closest homolog to beta -TRCP, Met30, does not associate with the Ikappa Balpha destruction motif (Fig. 1c). We therefore anticipated that yeast extracts shown previously to support SCF-dependent ubiquitination of Cln2 and Sic1 (Deshaies et al. 1995; Skowyra et al. 1997; Verma et al. 1997) would be inactive toward either phosphorylated or unphosphorylated Ikappa Balpha and this was the case (Fig. 6c, lanes 4,5). However, when these same reaction mixtures were supplemented with Flag-tagged SCFbeta -TRCP complexes isolated from 293T cells (Fig. 6a), Ikappa Balpha ubiquitination was observed (Fig. 6c, lane 7). The activity was dependent upon phosphorylation of Ikappa Balpha (lane 6) and was absent in reaction mixtures containing anti-Flag immunoprecipitates from mock-transfected cells (lanes 8,9). Moreover, SCFbeta -TRCP was unable to stimulate ubiquitination when mixed with E1, ATP, and ubiquitin in the absence of yeast extract (lane 10), indicating that a specific E2 activity is not efficiently immunoprecipitated with the SCFbeta -TRCP complex. As expected, the active SCFbeta -TRCP complexes associated with phosphorylated Ikappa Balpha while control immune complex did not (Fig. 6b).





View larger version (159K):
[in this window]
[in a new window]
 
Figure 6.   Stimulation of Ikappa Balpha -ubiquitin ligase activity by SCFbeta -TRCP in vitro. (a) Flag-tagged SCFbeta -TRCP was prepared after transient transfection in 293T cells by immunoprecipitation along with a Flag immune complex from mock-transfected cells. Immune complexes were analyzed for the presence of Cul1HA, Skp1Myc, and beta -TRCPFlag by immunoblotting (lanes 3,4). Crude lysates used for immunoprecipitation are shown as controls (lanes 1,2). (b) beta -TRCPFlag immune complexes associate with phosphorylated Ikappa Balpha in vitro. Immune complexes (10 µl beads) from (a) were incubated with 15 nM phosphorylated Ikappa Balpha /NF-kappa B complexes in a total volume of 100 µl. Washed beads were subjected to SDS-PAGE and Ikappa Balpha determined by immunobloting. The asterisk indicates a sample containing 15% of the input Ikappa Balpha complex. (c) Stimulation of Ikappa Balpha -ubiquitin ligase activity by SCFbeta -TRCP in vitro. Yeast extracts (supplemented with E1, ubiquitin, and an ATP-regenerating system) were incubated with unphosphorylated or phosphorylated Ikappa Balpha /NF-kappa B complexes (25 nM) in the presence of 10 µl of control immune complexes (lanes 8,9) or beta -TRCPFlag immune complexes (lanes 6,7). After 90 min, reaction mixtures were separated by SDS-PAGE and Ikappa Balpha detected by immunoblotting with anti-Ikappa Balpha antibodies. As controls, untreated Ikappa Balpha complexes (lanes 1,2), supplemented yeast lysates (lane 3), and an SCFbeta -TRCP immune complex reaction mixture containing all components except the yeast extract (lane 10) were also included. (d) Reconstitution of Ikappa Balpha ubiquitination activity in mammalian extracts by addition of purified GST-beta -TRCP. Reaction mixtures, prepared as described in Materials and Methods, contained E1, ubiquitin, ATP, HQ unbound as a source of E2 activity, and other components as indicated (lanes 1-6). Control reactions (lanes 7,8) lacked phenyl-Sepharose fraction 9. After 90 min, products were analyzed by SDS-PAGE and immunoblotting with anti-Ikappa Balpha antibodies.

In an alternative approach, we tested whether recombinant GST-beta -TRCP, purified to near homogeneity from insect cells (data not shown), could support ubiquitination of Ikappa Balpha in the mammalian ubiquitination system described in Figure 4. As noted above, fraction 9 from the phenyl-Sepharose column contains Cul1 and Skp1 but lacks detectable beta -TRCP and Ikappa Balpha ubiquitination activity (Fig. 6d, lane 1). However, when this fraction was supplemented with GST-beta -TRCP, a potent phosphorylation-dependent Ikappa Balpha -ubiquitin ligase activity was generated (Fig. 6d, lane 2). This activity was not observed when this fraction was supplemented with purified GST protein (Fig. 6d, lane 3). Also, addition of a phosphorylated Ikappa Balpha destruction motif peptide (but not the unphosphorylated peptide) completely blocked Ikappa Balpha ubiquitination (Fig. 6d, lanes 5,6). Finally, the activity was not observed when the GST-beta -TRCP protein was incubated in the reaction conditions lacking the phenyl-Sepharose fraction, suggesting a requirement for Cul1 and Skp1 (Fig. 6d, lane 7). Taken together, these two assay systems provide compelling evidence that SCFbeta -TRCP functions as an Ikappa B-ubiquitin ligase.

    Discussion
Top
Abstract
Introduction
Results
Discussion
Materials and methods
References

Activation of NF-kappa B involves an extensive signal transduction pathway that culminates in the destruction of the NF-kappa B inhibitor Ikappa Balpha . Although the protein kinase pathways that control the timing of NF-kappa B activation have been defined, the molecules responsible for the actual ubiquitination events have not been elucidated. In this work, we provide biochemical evidence that the WD-40-containing F-box protein, beta -TRCP, functions as a specificity factor in an SCF complex to promote signal-dependent ubiquitination of Ikappa Balpha (Fig. 7). A role for beta -TRCP in controlling Ikappa Balpha ubiquitination is supported by the following findings. (1) Destruction of Ikappa Balpha is known to require Ikappa K-dependent phosphorylation of residues (Ser-32 and Ser-36) located in a destruction motif. beta -TRCP and its SCF complex associate with this Ikappa Balpha destruction motif and with the Ikappa Balpha /NF-kappa B complex in a manner that is dependent upon phosphorylation of the Ikappa Balpha destruction motif. A variety of other F-box proteins, including two other WD-40 containing F-box proteins (Met30 and MD6), failed to associate with either phosphorylated or unphosphorylated Ikappa Balpha destruction motifs, pointing to the specificity of the interaction with beta -TRCP. We believe that the interaction between beta -TRCP and the Ikappa Balpha destruction motif is direct, as peptide beads containing this motif precipitate GST-beta -TRCP from insect cell lysates in the absence of other abundant proteins (J. Winston, S. Elledge, and J. Harper, unpubl.). (2) beta -TRCP forms a complex with two proteins, Skp1 and Cul1, that have been linked previously to phosphorylation-dependent ubiquitination. beta -TRCP is localized in the cytoplasm where Ikappa Balpha ubiquitination is thought to occur. (3) beta -TRCP copurifies with Ikappa Balpha -ubiquitin ligase activity from tissue culture cells, and these active fractions also contain Cul1 and Skp1. (4) Depletion of beta -TRCP with either anti-Skp1 antibodies or phosphorylated destruction motif peptides correlates with loss of Ikappa Balpha -ubiquitin ligase activity. (5) SCFbeta -TRCP complexes stimulated phosphorylation-dependent Ikappa Balpha -ubiquitin ligase activity when supplemented with E1, ubiquitin, ATP, and a yeast extract. These yeast extracts lack Ikappa Balpha -ubiquitin ligase despite the presence of multiple SCF complexes (Bai et al. 1996; Patton et al. 1998a,b), providing further evidence of a role for beta -TRCP as a specificity factor for Ikappa Balpha , but provide E2 activities and possibly other components that support Ikappa Balpha ubiquitination by the beta -TRCP complex. (6) Addition of beta -TRCP to fractions containing Cul1 and Skp1 but lacking Ikappa Balpha -ubiquitination activity leads to robust ubiquitination activity that is phosphorylation dependent and inhibited by a phosphorylated Ikappa Balpha destruction motif peptide. At present, we have been unable to reconstitute Ikappa Balpha -ubiquitin ligase activity using SCFbeta -TRCP complexes isolated from transfected cells and column fractions depleted of beta -TRCP by either anti-Skp1 antibodies or phospho-Ikappa Balpha peptides. This may reflect removal of an essential factor by depletion that is not present in sufficient levels in the transiently expressed SCF complex to support Ikappa Balpha ubiquitination but are provided in trans by yeast extracts or undepleted mammalian extracts. Taken together, these data provide strong evidence that SCFbeta -TRCP functions in Ikappa Balpha ubiquitination. After submission of this paper, Yaron et al. (1998) reported that beta -TRCP is a component of the Ikappa Balpha -ubiquitin ligase and demonstrated that mutants lacking the F-box stabilize Ikappa Balpha and block NF-kappa B activation in vivo. However, no data linking beta -TRCP to an SCF-dependent process was presented, and it was suggested that beta -TRCP might function independently of Cul1 and Skp1. Our data provide compelling and complementary biochemical evidence that beta -TRCP functions in the context of an SCF pathway, a result that has important mechanistic implications and further implicates the SCF pathway in phosphorylation-dependent ubiquitination reactions. Currently, the identity of the E2(s) involved in Ikappa Balpha ubiquitination in vivo is unknown, as is the nature of the heterogeneity observed with beta -TRCP. We note, however, that other F-box proteins including Skp2 are modified by phosphorylation (Lisztwan et al. 1998), and such modifications could potentially play regulatory roles. The methods we have employed offer two general approaches for determining whether a particular ubiquitination process involves an SCF complex: (1) Depletion of active fractions with Skp1 antibodies, and (2) the use of substrates as affinity reagents to examine association with cloned F-box proteins. The expanding number of F-box protein sequences available will greatly facilitate the identification of SCF-dependent processes through these types of approaches.


View larger version (28K):
[in this window]
[in a new window]
 
Figure 7.   Schematic representation of the proposed pathways controlling ubiquitin-mediated proteolysis of Ikappa Balpha and beta catenin. beta -TRCP, an F-box protein, is a component of an SCF-ubiquitin ligase. In response to appropriate signals (i.e., TNFalpha ), the Ikappa K complex is activated and phosphorylates Ikappa Balpha in complexes with NF-kappa B on Ser-32 and Ser-36. This complex is then recognized by beta -TRCP in an SCF complex, facilitating ubiquitination by an E1- and E2-dependent mechanism. beta Catenin, in complexes with APC, axin, and GSK3beta , is phosphorylated on Ser-33 and Ser-37. This phosphorylated beta -catenin can then associate with SCFbeta -TRCP, resulting in ubiquitination. It is not clear at present whether beta -catenin alone or the APC/beta -catenin complex is the relevant target. Yellow ovals indicate phosphorylation.

The sequence conservation of the Ikappa Balpha destruction motif with a region of beta -catenin implicated in its turnover, coupled with a genetic requirement for the beta -TRCP homolog slimb in turnover of the beta -catenin homolog Armadillo (Jiang and Struhl 1998), led us to address whether beta -TRCP might interact directly with beta -catenin. Phosphorylation of serine residues 33 and 37 was sufficient to allow for a peptide spanning this region to associate with beta -TRCP and its SCF complex but not other F-box proteins. beta -Catenin is a component of the Wingless/Wnt signaling pathway and functions with Tcf/Lef transcription factors to regulate patterning and other developmental decisions (Peifer 1997). Recent work has revealed that expression of a beta -TRCP protein lacking the F-box leads to accumulation of beta -catenin and ectopic activation of the Wnt pathway in Xenopus (Marikawa and Elinson 1998) and beta -catenin stabilization in mammalian cells (Latres et al. 1999). This, together with our data linking beta -TRCP to direct recognition of the phosphorylated beta -catenin destruction motif, strongly implicates SCFbeta -TRCP as the beta -catenin-ubiquitin ligase (Fig. 7). The levels of beta -catenin are regulated by the APC (adenomatous polyposis coli) tumor suppressor protein, axin, and the protein kinase GSK3beta (Korinek et al. 1997; Morin et al. 1997; Rubinfeld et al. 1997). Formation of an APC/axin/GSK3beta /beta -catenin complex is thought to be required to allow appropriate phosphorylation of beta -catenin by GSK3beta (Hart et al. 1998; Ikeda et al. 1998) and in the absence of Wnt signaling, beta -catenin levels remain low due to constitutive phosphorylation and ubiquitin-mediated proteolysis. Wnt signaling inactivates GSK3beta , leading to increased levels of beta -catenin and activation of transcription (Peifer 1997). Mutations in either the APC gene or in beta -catenin allow for beta -catenin accumulation (Morin et al. 1997; Rubinfeld et al. 1997). Such mutations are found in a large fraction of colon cancers (Morin et al. 1997